Orchid Chemicals & Pharmaceuticals is currently trading at Rs 150.25, up by 0.30 points or 0.20% from its previous closing of Rs 149.95 on the BSE.
The scrip opened at Rs 149.50 and has touched a high and low of Rs 153.40 and Rs 146.90 respectively. So far 205235 shares were traded on the counter.
The BSE group 'B' stock of face value Rs 10 has touched a 52 week high of Rs 324.65 on 04-Apr-2011 and a 52 week low of Rs 112.25 on 19-Dec-2011.
Last one week high and low of the scrip stood at Rs 154.30 and Rs 139.00 respectively. The current market cap of the company is Rs 1073.19 crore.
The promoters holding in the company stood at 29.83% while Institutions and Non-Institutions held 18.30% and 47.29% respectively.
Chennai-based global pharma major, Orchid Chemicals & Pharmaceuticals has received board’s approval for the scheme of amalgamation for the merger of company's wholly-owned subsidiary - Orchid Research Laboratories with itself. The company has received approval for the said scheme of amalgamation at its board meeting held on January 7, 2012.
Recently, Serum Institute of India (Serum) had hiked its stake in Orchid Chemicals & Pharmaceuticals. The institute had bought 5 lakh fresh shares for Rs 6.6 crore through open market transactions, according to the data available with the exchange.
Orchid is a pharmaceutical company engaged in development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs. The company was incorporated in the year 1992 as a 100% export-oriented unit.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: